Table 1. Characteristics of 670 patients with Crohn’s disease and poor prognostic factors.
| Early anti-TNF group (n = 79) | Early IM group (n = 286) | Late therapy group (n = 305) | Total (n = 670) | P value | |
|---|---|---|---|---|---|
| Male | 57 (72.2%) | 232 (81.1%) | 209 (68.5%) | 498 (74.3%) | 0.002 |
|
Mean age at diagnosis, years (mean±SD) ≤16 ≥17–40 |
21.0±5.8 20 (25.3%) 59 (74.7%) |
22.0±6.5 49 (17.1%) 237 (82.9%) |
22.0±6.3 59 (19.3%) 246 (80.7%) |
21.8±6.3 128 (19.1%) 542 (80.9%) |
0.669 0.259 |
|
Smoking status Never smoker Ex-smoker Current smoker |
59 (74.7%) 5 (6.3%) 15 (19.0%) |
202 (70.6%) 17 (6.0%) 67 (23.4%) |
217 (71.1%) 14 (4.6%) 74 (24.3%) |
478 (71.3%) 36 (5.4%) 156 (23.3%) |
0.817 |
| Family history of IBD | 12 (15.2%) | 20 (7.0%) | 16 (5.2%) | 48 (7.2%) | 0.009 |
|
Location at diagnosis Ileum only (L1) Colon only (L2) Ileocolon (L3) |
11 (13.9%) 3 (3.8%) 65 (82.3%) |
29 (10.1%) 16 (5.6%) 241 (84.3%) |
43 (14.1%) 18 (5.9%) 244 (80.0%) |
83 (12.4%) 37 (5.5%) 550 (82.1%) |
0.579 |
|
Behavior at diagnosis Non-stricturing and non-penetrating (B1) Stricturing (B2) Penetrating (B3) |
79 (100%) |
286 (100%) |
305 (100%) |
670 (100%) |
|
|
Perianal fistula at diagnosis Status of perianal fistula at diagnosis Healed state Active state Unknown state |
54 (68.4%) 14 (17.7%) 39 (49.4%) 1 (1.3%) |
186 (65.0%) 56 (19.6%) 129 (45.1%) 1 (0.3%) |
212 (69.5%) 87 (28.5%) 123 (40.3%) 2 (0.7%) |
452 (67.5%) 157 (23.4%) 291 (43.4%) 4 (0.7%) |
0.502 0.142 0.016 0.265 0.635 |
|
Corticosteroid use Time to corticosteroid use, months (mean±SD) |
65 (82.3%) 1.74±7.63 |
197 (68.9%) 2.35±8.64 |
237 (77.7%) 19.85±38.52 |
499 (74.5%) 10.58±28.60 |
< 0.001 < 0.001 |
|
IM use Time to IM use, months (mean±SD) |
72 (91.1%) 5.97±14.35 |
286 (100%) 5.02±6.27 |
291 (95.4%) 71.08±44.12 |
649 (96.9%) 34.75±44.56 |
< 0.001 < 0.001 |
|
Anti-TNF use Time to anti-TNF, months (mean±SD) |
79 (100%) 11.56±6.28 |
0 (0%) NA |
154 (50.5%) 109.40±58.34 |
233 (34.8%) 76.22±66.43 |
< 0.001 < 0.001 |
| Mean follow-up duration, months (mean±SD) | 76.60±31.20 | 84.72±40.85 | 157.05±58.29 | 116.69±61.14 | < 0.001 |
IM, immunomodulator; SD, standard deviation; IBD, inflammatory bowel disease; NA, not applicable